Protein-Tyrosine Kinases
"Protein-Tyrosine Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.
Descriptor ID |
D011505
|
MeSH Number(s) |
D08.811.913.696.620.682.725
|
Concept/Terms |
Protein-Tyrosine Kinases- Protein-Tyrosine Kinases
- Kinases, Protein-Tyrosine
- Protein Tyrosine Kinases
- Tyrosine Kinase
- Kinase, Tyrosine
- Tyrosine Protein Kinase
- Kinase, Tyrosine Protein
- Tyrosylprotein Kinase
- Kinase, Tyrosylprotein
- Tyrosine-Specific Protein Kinase
- Kinase, Tyrosine-Specific Protein
- Protein Kinase, Tyrosine-Specific
- Tyrosine Specific Protein Kinase
- Tyrosine-Specific Protein Kinases
- Kinases, Tyrosine-Specific Protein
- Protein Kinases, Tyrosine-Specific
- Tyrosine Specific Protein Kinases
- Protein-Tyrosine Kinase
- Kinase, Protein-Tyrosine
- Protein Tyrosine Kinase
- Tyrosine Protein Kinases
- Kinases, Tyrosine Protein
- Protein Kinases, Tyrosine
|
Below are MeSH descriptors whose meaning is more general than "Protein-Tyrosine Kinases".
Below are MeSH descriptors whose meaning is more specific than "Protein-Tyrosine Kinases".
This graph shows the total number of publications written about "Protein-Tyrosine Kinases" by people in UAMS Profiles by year, and whether "Protein-Tyrosine Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2024 | 1 | 0 | 1 | 2022 | 1 | 0 | 1 | 2021 | 1 | 0 | 1 | 2020 | 2 | 1 | 3 | 2019 | 3 | 0 | 3 | 2018 | 0 | 1 | 1 | 2017 | 2 | 0 | 2 | 2016 | 0 | 1 | 1 | 2015 | 3 | 0 | 3 | 2014 | 3 | 2 | 5 | 2013 | 1 | 1 | 2 | 2012 | 2 | 0 | 2 | 2011 | 1 | 1 | 2 | 2010 | 0 | 2 | 2 | 2008 | 1 | 1 | 2 | 2007 | 1 | 0 | 1 | 2006 | 3 | 1 | 4 | 2005 | 2 | 1 | 3 | 2004 | 2 | 4 | 6 | 2003 | 4 | 3 | 7 | 2002 | 2 | 3 | 5 | 2001 | 2 | 1 | 3 | 2000 | 1 | 2 | 3 | 1999 | 0 | 2 | 2 | 1998 | 2 | 0 | 2 | 1997 | 1 | 1 | 2 | 1996 | 1 | 1 | 2 | 1995 | 0 | 2 | 2 | 1994 | 3 | 0 | 3 | 1990 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Protein-Tyrosine Kinases" by people in Profiles over the past ten years.
-
Li J, Xiong N, West KL, Leung M, Ching YP, Huang J, Yuan J, Yu CH, Leung J, Huen M. Nuclear F-actin assembly on damaged chromatin is regulated by DYRK1A and Spir1 phosphorylation. Nucleic Acids Res. 2024 Aug 27; 52(15):8897-8912.
-
Taniguchi H, Caeser R, Chavan SS, Zhan YA, Chow A, Manoj P, Uddin F, Kitai H, Qu R, Hayatt O, Shah NS, Quintanal Villalonga ?, Allaj V, Nguyen EM, Chan J, Michel AO, Mukae H, de Stanchina E, Rudin CM, Sen T. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell Rep. 2022 05 17; 39(7):110814.
-
Peretti D, Smith HL, Verity N, Humoud I, de Weerd L, Swinden DP, Hayes J, Mallucci GR. TrkB signaling regulates the cold-shock protein RBM3-mediated neuroprotection. Life Sci Alliance. 2021 04; 4(4).
-
Yazici Y, McAlindon TE, Gibofsky A, Lane NE, Clauw D, Jones M, Bergfeld J, Swearingen CJ, DiFrancesco A, Simsek I, Tambiah J, Hochberg MC. Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial. Arthritis Rheumatol. 2020 10; 72(10):1694-1706.
-
Dong C, West KL, Tan XY, Li J, Ishibashi T, Yu CH, Sy SMH, Leung JWC, Huen MSY. Screen identifies DYRK1B network as mediator of transcription repression on damaged chromatin. Proc Natl Acad Sci U S A. 2020 07 21; 117(29):17019-17030.
-
Huang L, Ye K, McGee MC, Nidetz NF, Elmore JP, Limper CB, Southard TL, Russell DG, August A, Huang W. Interleukin-2-Inducible T-Cell Kinase Deficiency Impairs Early Pulmonary Protection Against Mycobacterium tuberculosis Infection. Front Immunol. 2019; 10:3103.
-
Miah S, Banks CAS, Ogunbolude Y, Bagu ET, Berg JM, Saraf A, Tettey TT, Hattem G, Dayebgadoh G, Kempf CG, Sardiu M, Napper S, Florens L, Lukong KE, Washburn MP. BRK phosphorylates SMAD4 for proteasomal degradation and inhibits tumor suppressor FRK to control SNAIL, SLUG, and metastatic potential. Sci Adv. 2019 10; 5(10):eaaw3113.
-
Melchior B, Mittapalli GK, Lai C, Duong-Polk K, Stewart J, G?ner B, Hofilena B, Tjitro A, Anderson SD, Herman DS, Dellamary L, Swearingen CJ, Sunil KC, Yazici Y. Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease. Aging Cell. 2019 10; 18(5):e13000.
-
Miah S, Bagu E, Goel R, Ogunbolude Y, Dai C, Ward A, Vizeacoumar FS, Davies G, Vizeacoumar FJ, Anderson D, Lukong KE. Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells. BMC Cancer. 2019 Jan 16; 19(1):78.
-
Morgan GJ, He J, Tytarenko R, Patel P, Stephens OW, Zhong S, Deshpande S, Bauer M, Weinhold N, Schinke C, Rasche L, Bailey M, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Zangari M, van Rhee F, Mughal T, Davies FE, Walker BA. Kinase domain activation through gene rearrangement in multiple myeloma. Leukemia. 2018 11; 32(11):2435-2444.
-
Kannan AK, Mohinta S, Huang W, Huang L, Koylass N, Appleton JA, August A. T-Bet independent development of IFN? secreting natural T helper 1 cell population in the absence of Itk. Sci Rep. 2017 04 13; 7:45935.
-
Bagu ET, Miah S, Dai C, Spriggs T, Ogunbolude Y, Beaton E, Sanders M, Goel RK, Bonham K, Lukong KE. Repression of Fyn-related kinase in breast cancer cells is associated with promoter site-specific CpG methylation. Oncotarget. 2017 Feb 14; 8(7):11442-11459.
-
Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol. 2016 10 01; 90(19):8924-33.
-
Wei W, Birrer MJ. Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer. Cancer Cell. 2015 Jul 13; 28(1):7-9.
-
Arnaoutakis K. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2015 02 12; 372(7):683.
-
Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E, Xu H, Huang J, Tao Y, Hao M, Franqui R, Levasseur D, Janz S, Tricot G, Zhan F. Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. Cancer Res. 2015 Feb 01; 75(3):594-604.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|